A Contemporary Report Of Clinical Outcomes Associated With Impella 5.5 In Patients With Cardiogenic Shock

Sana Riaz,Ippokratis Konstantinidis,Maciej Tysarowski,Jason Gluck,Ayyaz Ali,Abhishek Jaiswal

DOI: https://doi.org/10.1016/j.cardfail.2023.10.287

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction Implantation of the Impella 5.5, a temporary ventricular assist device (VAD), can deliver flow up to 5.5 L/min, which can reverse cardiogenic shock and end-organ damage and aid bridge to recovery, transplant, or durable VAD. In addition, a transaxillary implantation promotes patient mobility and rehabilitation while awaiting final destination therapy. Hypothesis We sought to assess survival and complications in patients who underwent Impella 5.5 support. Methods A retrospective of consecutive adults who underwent implantation of the Impella 5.5 at our center. Results Fifteen consecutive patients underwent implantation from July 2021 through March 2023; mean age 58 years (SD±12), 80% were men, 53% were white, and decompensated chronic heart failure was the most common indication (73%). The mean pre-implantation cardiac output and cardiac index were 4 LPM (SD±1.2) and 1.9 LPM/m2 (SD±0.5), respectively. Of the 15 patients, 53% and 20% of patients were transitioned from intra-aortic balloon pump and veno-arterial extracorporeal membrane oxygenation, respectively. The right axillary artery graft (80%) was the most common implantation site, followed by central cannulation (20%). The median duration of support was 19 days (IQR 13,25), 53% of patients were on support for >2 weeks, and the longest duration of support was 60 days. Post-implantation, 73% of patients required inotropic support with at least one agent. There was an improvement in glomerular filtration rate (GFR) and liver function tests (LFTs) in 53% and 40% of patients, respectively. The mean duration for these improvements was within two weeks [GFR 9 days (SD±9), and LFTs 14 days (SD±7)]. There was no brachial plexus injury, graft infection, valve injury, or stroke. There was no incidence of pump failure or pump thrombosis. The most common complication was hemolysis (serum LDH > 500 U/L) combined with the clinical presentation (27%), followed by insertion site hematoma (20%), requiring blood transfusions in 40% of patients. Acute kidney injury, an increase in serum creatinine ≥ 0.3 mg/dL, was found in 7%, and none developed an acute liver injury. Survival to device explant was 73%. Of the survivors, 40% underwent a heart transplant, 20% underwent durable left ventricular assist device (LVAD) implantation, and 13% recovered. Death occurred in 27% due to multiorgan dysfunction (2), withdrawal of care (1), and both (1). Conclusions We report a favorable clinical outcome with Impella 5.5 at our center, with around 75% survival and a bridge to destination beyond the suggested 14-day support. Complications were limited to insertion site hematoma without any permanent injury.

cardiac & cardiovascular systems